Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol 2020 Apr;82(4):936-945
Date
12/07/2019Pubmed ID
31809827DOI
10.1016/j.jaad.2019.11.040Scopus ID
2-s2.0-85078983517 (requires institutional sign-in at Scopus site) 69 CitationsAbstract
BACKGROUND: Long-term maintenance treatment is required for patients with psoriasis.
OBJECTIVES: To evaluate the efficacy and safety of guselkumab in patients with moderate to severe psoriasis through 3 years of treatment.
METHODS: In 2 ongoing, phase 3 trials of guselkumab (VOYAGE 1 and VOYAGE 2), the proportions of patients achieving at least 90% and 100% improvement in the Psoriasis Area and Severity Index (PASI 90 and PASI 100, respectively) and Investigator's Global Assessment (IGA) scores of 0/1 and 0 were summarized for the guselkumab group (including placebo-to-guselkumab crossover). Patients who met treatment failure rules were considered nonresponders. Safety outcomes (rates/100 patient-years [PY]) were evaluated based on data pooled across studies through week 156.
RESULTS: Three-year response rates for the guselkumab group in VOYAGE 1 and VOYAGE 2, respectively, were 82.8% and 77.2% for PASI 90, 50.8% and 48.8% for PASI 100, 82.1% and 83.0% for IGA score of 0/1, and 53.1% and 52.9% for IGA score of 0. Safety event rates across studies occurred through week 156 as follows: serious adverse events, 5.68/100 PY; serious infections, 1.15/100 PY; nonmelanoma skin cancers, 0.28/100 PY; malignancies other than nonmelanoma skin cancer, 0.47/100 PY; and major adverse cardiovascular events, 0.28/100 PY. Week 156 and week 100 rates were consistent.
LIMITATIONS: There was no comparator arm beyond 1 year.
CONCLUSIONS: Guselkumab shows durable efficacy and a consistent safety profile in patients with moderate to severe psoriasis treated for up to 3 years.
Author List
Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt AAuthor
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdalimumabAdult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Cross-Over Studies
Double-Blind Method
Female
Follow-Up Studies
Humans
Interleukin-23 Subunit p19
Male
Middle Aged
Patient Reported Outcome Measures
Placebos
Psoriasis
Severity of Illness Index
Treatment Outcome
Young Adult